According to the latest announcement on the Chinese Drug Clinical Trial Registration and Information Disclosure Platform, Merck's Class 1 oral drug MK-3543 (bomedemstat) for the treatment of primary thrombocytopenia has started Phase 3 clinical trials. Bomedemstat is an oral lysine specific demethylase 1 (LSD1) inhibitor, which Merck acquired from Imago BioSciences for approximately $1.35 billion in 2022.